<DOC>
	<DOCNO>NCT00481143</DOCNO>
	<brief_summary>The purpose study investigate effect iron chelation use deferasirox low INT-1 risk ( refer international prognostic scoring system , IPSS ) MDS patient show sign iron overload due repeat blood transfusion . This trial recruit patient United States .</brief_summary>
	<brief_title>Efficacy Safety Deferasirox Patients With Myelodysplastic Syndrome Transfusion-dependent Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>MDS patient present low intermediate1 IPSS risk transfusional iron overload Patients either gender age ≥ 18 year History least 20 unit red blood cell transfusion 100mL/kg prepacked red blood cell ( PRBCs ) Patients either naïve iron chelation prior treatment deferoxamine ( DFO ) deferiprone ( L1 ) Females childbearing potential must use doublebarrier contraception , oral contraceptive plus barrier contraceptive , must undergo clinically document total hysterectomy and/or oophorectomy , tubal ligation postmenopausal define amenorrhea least 12 month . Nontransfusion relate iron overload Treatment deferasirox ( ICL670 ) study start Patients concomitant malignant disease Patients range lab value History nephrotic syndrome Patients previous history clinically relevant ocular toxicity relate iron chelation Systemic disease ( cardiovascular , renal , hepatic , etc . ) would prevent patient undergo study treatment Patients treat systemic investigational drug within past 4 week topical investigational drug within past 7 day Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . Patients active uncontrolled infectious disease Pregnancy breast feed Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>iron overload</keyword>
	<keyword>chelation</keyword>
	<keyword>chelators</keyword>
	<keyword>ICL670</keyword>
	<keyword>Deferasirox</keyword>
	<keyword>serum ferritin</keyword>
	<keyword>LIC</keyword>
	<keyword>transfusional hemosiderosis</keyword>
	<keyword>Refractory Anemia</keyword>
	<keyword>RA</keyword>
	<keyword>Refractory Anemia Ringed Sideroblasts</keyword>
	<keyword>RARS</keyword>
	<keyword>blood transfusion</keyword>
	<keyword>Mydelodysplastic Syndrome ( )</keyword>
</DOC>